Drug Trial Radar · NCT01172808
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
Last checked: Nov 19, 2026Latest source record: Jun 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,071
Actual
Start
Aug 2010
Primary completion
Nov 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Jul 30, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 mcg tiotropium over a 24-week treatment period as compared to placebo and salmeterol (50 mcg twice daily). Tiotropium inhalation solution delivered by the Respimat® inhaler will be examined on top of maintenance treatment with inhaled corticosteroid controller medication in patients with moderate persistent asthma. Efficacy and safety will be assessed by measuring effects on lung function, effects on asthma exacerbations, effects on quality of life, effects on asthma control, effects on health care resource utilisation, and number of adverse events.
Conditions
- Asthma
Interventions
PlaceboDrug
Placebo that represents comparator
tiotropium Respimat® low doseDrug
IMP
PlaceboDrug
Placebo that represents comparator
PlaceboDrug
Placebo that represents comparator
tiotropium Respimat® high doseDrug
IMP
50 mcg salmeterol HFA MDIDrug
Active comparator
PlaceboDrug
Placebo that represents BI drug
PlaceboDrug
Placebo that represents BI drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak FEV1 Within 3 Hours Post-dose ResponseTime frame: 24 weeks
- Trough FEV1 ResponseTime frame: 24 weeks
- The Responder Rate as Assessed by the ACQ From the Two Twin Trials 205.419 (NCT01172821) and the Present 205.418 (NCT01172808)Time frame: 24 weeks
Locations
114 sites in 11 countries. Site status is shown where the registry gives one.
205.418.01020 Boehringer Ingelheim Investigational Site
Huntington Beach, California
205.418.01002 Boehringer Ingelheim Investigational Site
Mission Viejo, California
205.418.01014 Boehringer Ingelheim Investigational Site
San Diego, California
205.418.01011 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado
205.418.01004 Boehringer Ingelheim Investigational Site
Coeur d'Alene, Idaho
205.418.01017 Boehringer Ingelheim Investigational Site
Normal, Illinois
205.418.01008 Boehringer Ingelheim Investigational Site
South Bend, Indiana
205.418.01012 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
205.418.01013 Boehringer Ingelheim Investigational Site
North Dartmouth, Massachusetts
205.418.01015 Boehringer Ingelheim Investigational Site
North Dartmouth, Massachusetts
205.418.01009 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota
205.418.01006 Boehringer Ingelheim Investigational Site
Bellevue, Nebraska
205.418.01016 Boehringer Ingelheim Investigational Site
Boys Town, Nebraska
205.418.01003 Boehringer Ingelheim Investigational Site
Omaha, Nebraska
205.418.01021 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina
205.418.01018 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma
205.418.01005 Boehringer Ingelheim Investigational Site
Charleston, South Carolina
205.418.01010 Boehringer Ingelheim Investigational Site
Easely, South Carolina
205.418.01007 Boehringer Ingelheim Investigational Site
Dallas, Texas
205.418.01019 Boehringer Ingelheim Investigational Site
Seattle, Washington
205.418.01001 Boehringer Ingelheim Investigational Site
Tacoma, Washington
205.418.55002 Boehringer Ingelheim Investigational Site
Juiz de Fora, Brazil
205.418.55001 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
205.418.55004 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
205.418.55005 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
205.418.55003 Boehringer Ingelheim Investigational Site
Rio de Janeiro - RJ, Brazil
205.418.86001 Boehringer Ingelheim Investigational Site
Beijing, China
205.418.86005 Boehringer Ingelheim Investigational Site
Beijing, China
205.418.86007 Boehringer Ingelheim Investigational Site
Beijing, China
205.418.86012 Boehringer Ingelheim Investigational Site
Beijing, China
205.418.86014 Boehringer Ingelheim Investigational Site
Changsha, China
205.418.86011 Boehringer Ingelheim Investigational Site
Chengdu, China
205.418.86015 Boehringer Ingelheim Investigational Site
Chengdu, China
205.418.86003 Boehringer Ingelheim Investigational Site
Chongqing, China
205.418.86010 Boehringer Ingelheim Investigational Site
Guangzhou, China
205.418.86013 Boehringer Ingelheim Investigational Site
Kunming, China
205.418.86008 Boehringer Ingelheim Investigational Site
Qingdao, China
205.418.86002 Boehringer Ingelheim Investigational Site
Shanghai, China
205.418.86004 Boehringer Ingelheim Investigational Site
Shenyang, China
205.418.86009 Boehringer Ingelheim Investigational Site
Shenyang, China
Showing 40 of 114 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.